MedTrace Logo

FNA Tumor Sampling for CD137 Modulation: A Pilot Study

NCT01114256 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2017-08-03

No results posted yet for this study

Summary

The purpose of this study is to better understand the biology of the body's immune response to monoclonal antibody therapy for cancer. Your health information will be used to identify your tissues. The tissue we obtain may be useful for research or education, resulting in new drugs, therapies or diagnostic procedures.

Conditions

Interventions

PROCEDURE

FNA Biopsy

Sponsors & Collaborators

Principal Investigators

  • Dr. A. Dimitrios Colevas · Stanford University

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114256 on ClinicalTrials.gov